[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597382":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":32,"locations":38,"responsibleParty":60,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":10,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with DLBCL Treated with R-CHOP (Observational Group)",null,"Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who are receiving R-CHOP chemotherapy as part of standard clinical care. This observational study aims to evaluate the predictive value of baseline inflammatory markers (CRP, albumin, CAR, and mGPS) on treatment response and toxicity. No study-specific interventions are administered.",[13],"Drug: Observational Assessment of Standard R-CHOP Treatment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Observational Assessment of Standard R-CHOP Treatment","Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.",[9],[21,25,28,30],{"name":22,"affiliation":23,"role":24},"Mahmoud M Ellithy, MD","Faculty of Medicine, Ain Shams University","PRINCIPAL_INVESTIGATOR",{"name":26,"affiliation":23,"role":27},"Shaimaa A Pessar, MD","STUDY_DIRECTOR",{"name":29,"affiliation":23,"role":27},"Reham M Faheim, MD",{"name":31,"affiliation":23,"role":27},"Doaa A Mohamed, MD",[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Alaa M Elsayed, MSc","CONTACT","+201112490913","alaa.abdou@med.asu.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University","RECRUITING","Cairo","Cairo Governorate","1181","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.24967,30.06263,{"lat":51,"lon":50},[54,56,58],{"name":34,"role":35,"phone":55,"phoneExt":10,"email":37},"+20 111 249 0913",{"name":31,"role":35,"phone":10,"phoneExt":10,"email":57},"Doaa.atef@med.asu.edu.eg",{"name":34,"role":59,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100597382","predictive-value-of-crp-albumin-car-and-mgps-in-treatment-outcomes-of-dlbcl-100597382",false,"NCT07057765","Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL","Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 65 years\n* Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)\n* Any stage of disease (nodal or extra-nodal), with or without B symptoms\n* Scheduled to receive standard systemic treatment (R-CHOP)\n* ECOG performance status 0-2\n* Baseline normal:\n* Complete blood count (CBC)\n* Hepatitis viral markers\n* Liver and renal function tests\n* Urine analysis\n* Echocardiogram\n* Additional investigations to exclude current infection if clinically indicated\n\nExclusion Criteria:\n\n* History of other concurrent or previous malignancies\n* Relapsed or refractory DLBCL\n* Uncontrolled comorbid conditions that may interfere with study participation, including:\n* Diabetes mellitus\n* Autoimmune diseases\n* Active infections\n* Chronic inflammatory diseases\n* Cardiac dysfunction\n* Liver cell failure\n* Pregnant females","ALL","18 Years","65 Years",{"count":73,"type":74},40,"ESTIMATED","OBSERVATIONAL","This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.",[78,79],"DLBCL - Diffuse Large B Cell Lymphoma","Markers of Inflammation",[81,82,83,84,85],"DLBCL","CRP To Albumin Ratio","CAR","modified Glassgow Prognostic Score","mGPS","2025-07-06",{"date":88,"type":89},"2025-07-10","ACTUAL",{"date":91,"type":89},"2025-05-05",{"date":93,"type":74},"2026-08",{"name":5,"class":6},1]